CTRC, a NCI-Designated Cancer Center and part of University of Texas Health Science Center at San Antonio, Joins the Caris Centers of Excellence for Precision Medicine Network to Help Develop Guidelines and Standards of Care for Tumor Profiling IRVING, Texas, July 25, 2016 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the
Read more →IRVING, Tex., June 7, 2016 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, today announced the presentation of a retrospective study introducing time-to-next treatment (TNT) as a surrogate measure predicting outcomes in patients with advanced cancer at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read more →Research Demonstrates Clinical Utility of Caris Molecular Intelligence and Illustrates the Positive Impact Following its Proprietary Recommendations can have on the Treatment and Survival of Cancer Patients IRVING, Tex., May 31, 2016 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, announced today the acceptance of 19 clinical
Read more →Late-Breaking Study Highlights Diagnostic Utility of Caris’ Revolutionary and Proprietary ADAPT Biotargeting System IRVING, Tex., April 11, 2016 – Caris Life Sciences®, a leading biotechnology company focused on fulfilling the promise of precision medicine, announced today that the Company will deliver 10 poster presentations at the 2016 American Association for Cancer Research (AACR) Annual Meeting
Read more →IRVING, Tex., Mar. 16, 2016 – Caris Life Sciences® today announced that the United States Patent and Trademark Office has recently provided notice of allowances for two of Caris’ pending patent applications: United States Patent Application Nos. 14/187,015 (“ ’015 Application”) and 14/249,261 (“ ’261 Application”). The patents that issue will provide intellectual property protection
Read more →